Skip to main content
Equibles
GRDN logo

GRDN · Guardian Pharmacy Services, Inc. · Metrics

Track GRDN — free

Use GRDN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GRDN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$39.56 +0.37 (+0.94%) At close · Oct 27 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$2.48B
Shares
63.34M
Volume · Oct 27 357.19K Avg daily vol (3M) 492.22K

GRDN metrics

72 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$39.56
Market cap
$2.48B

Price action

20 metrics
Price change (1W)
-2.4%
Price change (30D)
-3.8%
Price change (3M)
-5.5%
Price change (6M)
+3.3%
Price change (YTD)
+30.2%
Price change (1Y)
+37.4%
Trailing year
Price change (5Y)
—
52-week high
$48.00
52-week low
$27.03
Change from 52-week high
-18.4%
Change from 52-week low
+45.0%
Annualized volatility
41.1%
Annualized volatility (3M)
44.7%
Beta
0.6
RSI (14D)
42.8
Price vs SMA 50
-4.1%
Price vs SMA 200
+3.4%
Avg volume (3M)
491,585
Relative volume
0.4
Average dollar volume
$20.50M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
63.34M

Valuation

12 metrics
P / E (TTM)
37.9
Trailing earnings · reciprocal yield 2.6%
PEG ratio
—
EV / revenue
1.6×
reciprocal yield 60.8%
EV / EBITDA
22.1×
reciprocal yield 4.5%
EV / EBIT
28.2×
reciprocal yield 3.5%
P / sales
1.7×
reciprocal yield 58.6%
P / book
9.7
reciprocal yield 10.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
25.3
reciprocal yield 4.0%
Earnings yield
2.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
21.6%
Operating margin
5.8%
Trailing 12 months
Net margin
4.5%
Gross profit (TTM)
$316.58M
Operating profit (TTM)
$85.44M
Net income (TTM)
$65.91M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
30.6%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+2.2%
Year over year
Net income growth YoY
+142.2%
Revenue (TTM)
$1.46B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
25.6%
Return on assets
14.9%
Debt / equity
0.0
Current ratio
1.7
EBITDA (TTM)
$108.80M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
135.4
Net debt / EBITDA
-0.8
Return on invested capital
35.3%
Trailing 12 months
Net cash
$89.81M
Latest balance sheet
Cash & equivalents
$89.81M
Total assets
$443.58M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$98.86M
Capital expenditures (TTM)
$4.50M
R&D (TTM)
—
SG&A (TTM)
$231.14M
Stock compensation (TTM)
$10.23M
R&D / revenue
—
Stock compensation / revenue
0.7%

Ownership (13F)

9 metrics
13F filers
190
13F filer change QoQ
+19
Institutional ownership
46.7%
Conviction holders (share of 13F filers)
1.1%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+4.7%
Holder tenure
5.2
Price vs estimated holder cost
+39.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.8%

Short interest

3 metrics
Short interest
3.8%
Latest settlement · 5.3 days to cover
Days to cover
5.3d
Short-squeeze score
49 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1802255 CUSIP 40145W101 13F (30d) 19 filings 19 filers Visit website Investor relations